GLP-1 insurance coverage is shrinking, with insurers covering weight loss drugs down from 57 percent to 53 percent between 2025 and 2026. Roughly 12% of Americans use GLP-1 drugs, and coverage rules are changing for some people who take them for weight loss. Ideastream Public Media reported on the shift, its cost pressures, and options that may be available after a denial or coverage change.
The figures reflect a pullback in coverage for weight loss, not a blanket loss of coverage for every use of these medicines. Plan rules differ. A drug may be covered for Type 2 diabetes or another qualifying diagnosis while excluded for weight management. The plan’s current formulary and authorization rules determine the available coverage.
Why Insurers Are Pulling Back on GLP-1 Coverage
The monthly list price for GLP-1 drugs can run from about $500 to more than $1,000. That represents roughly $6,000 to more than $12,000 per patient each year before discounts or negotiated prices. When a growing share of a workforce uses these drugs, the expense can add up across an employer’s health plan.
WTW’s 2026 employer survey found that coverage for weight loss drugs declined for the first time in three years, from 57% to 53%. Among employers still covering the drugs, 30% were considering ending coverage. Of employers that had dropped or were considering dropping it, 91% cited high cost.
USA Today reporting published November 8 also described a decline in large employers covering GLP-1s for obesity. The report said Starbucks, PepsiCo, Cigna, and PwC had eliminated weight loss coverage while generally continuing coverage for diabetes. These employer decisions do not establish what any particular health plan covers. Individual plan documents remain controlling.
What a GLP-1 Coverage Denial Can Look Like
A coverage change or denial may not mean that every path to coverage has closed. The reason for the prescription and the plan’s rules matter. A plan may exclude weight loss use but continue to cover a medicine for obstructive sleep apnea, MASH, or Type 2 diabetes, subject to its criteria.
KFF Health News reported the case of Deborah Finley, a California resident whose plan gave 90 days’ notice that it would stop covering Zepbound for weight loss. Her plan still covered the drug for certain diagnoses, including obstructive sleep apnea or MASH. A prior-authorization request was denied after supporting records, including sleep-study information, did not reach the appropriate reviewers. The case shows why it is useful to check both the coverage rule and the documents submitted.
Five-Step Checklist: How to Appeal a Weight Loss Drug Denial
A weight loss drug coverage denial can be appealed, although approval is not guaranteed. The following steps can help organize a GLP-1 appeal:
-
Read the formulary and denial notice. Check whether the drug is excluded for weight management or whether the plan allows coverage for specified diagnoses. Conditions listed in reporting include sleep apnea, MASH, Type 2 diabetes, cardiovascular disease, and kidney disease. The plan’s own criteria control.
-
Ask the treating clinician to review relevant diagnoses. A clinician can determine whether screening or testing is medically appropriate. Johns Hopkins researcher Caleb Alexander told KFF Health News that undiagnosed diabetes may be a likely route from not meeting a plan’s criteria to meeting them. Screening should be based on clinical judgment, not pursued solely to obtain coverage.
-
Request the prior-authorization record. Ask what information was submitted and what the plan received. Confirm that relevant records, such as sleep-study results, were included and routed for review. Finley’s experience, described in the KFF Health News coverage guide, illustrates how missing documentation can affect a decision.
-
Submit supporting evidence with the appeal. Include the diagnosis and relevant clinical notes, records of other medications tried and their results, and documentation of participation in any nutrition or physical-activity program required by the plan. Keep copies and note submission dates. More than one appeal may be needed.
-
Ask the doctor’s office to help lead the process. The prescriber’s office may be familiar with the plan’s authorization forms and medical-necessity requirements. Patients are not required to manage the process without clinical support, and clinician involvement can help ensure relevant records are included.
Four Options If Your Plan Drops GLP-1 Coverage
The available routes depend on the person’s coverage, clinical circumstances, and eligibility. No option guarantees access or a specific price.
| Option | What to check |
|---|---|
| Appeal for medical-necessity coverage | Review the denial reason and plan rules. Submit clinical documentation through the plan’s appeal process. |
| Manufacturer self-pay programs | Reported starting self-pay prices include Wegovy from $150 and Foundayo around $150–$350 through a Lilly savings program. Eligibility, terms, and prices may change. |
| Medicare GLP-1 Bridge | Eligible Part D beneficiaries may pay $50 per month for covered products under the temporary program. Eligibility and cost-sharing limitations apply. |
| Compare plans during enrollment | Review each available plan’s formulary, coverage conditions, and total costs before enrolling. A new plan may also have different authorization requirements. |
Where eligible, HSA or FSA funds may be another way to pay qualified expenses with pretax dollars. A clinician can also discuss other prescription options, including Contrave or generic naltrexone-bupropion, if appropriate. Compounded GLP-1s are not FDA-approved. Anyone considering an online pharmacy should check the National Association of Boards of Pharmacy’s verification tool at safe.pharmacy and maintain physician oversight.
On Medicare? The $50 GLP-1 Bridge Runs Through 2027
The Medicare GLP-1 Bridge is a temporary CMS demonstration scheduled to run from July 1, 2026, through December 31, 2027. The program covers Foundayo, Wegovy, and Zepbound KwikPen for eligible beneficiaries with Part D drug coverage. Eligibility includes age 18 or older and specified BMI and health-condition criteria; a clinician must provide a prescription, and prior authorization may be required.
The $50 monthly copay is outside the Part D benefit. The Part D deductible does not apply, the copay does not count toward Part D out-of-pocket costs (TrOOP), and Extra Help does not lower it. The program is not limited to people age 65 and older; eligibility depends on Part D enrollment and the program’s clinical criteria. Details and eligibility can be checked on Medicare.gov’s weight-loss drug page, or through 1-800-MEDICARE.
Check the Formulary Before Switching Plans
The 2027 Marketplace open enrollment period is underway. In most states, it runs from November 1 through January 15; December 15 is generally the deadline for coverage beginning January 1. Dates can vary by state.
Before enrolling, check whether the specific medicine appears on the plan’s formulary and whether coverage applies to the intended use. Review prior authorization, step therapy, quantity limits, and cost sharing. A plan’s listing of a drug does not by itself confirm that a prescription will be approved.
Verify the Person Giving Insurance Advice
An agent, broker, or plan finder providing insurance advice should be appropriately licensed for the relevant state and type of coverage. License verification and National Producer Number (NPN) lookup are state-specific. Ohio readers can review insurance agent listings here; people in other states can use the directory for their state. Directory information should be independently confirmed with the relevant state insurance department.
Frequently Asked Questions
Will insurance still cover Ozempic if I have diabetes?
Many plans continue to cover GLP-1 medicines for Type 2 diabetes, subject to formulary and prior-authorization rules. Coverage changes described here primarily concern use for weight loss. Current plan terms should be checked.
Can I appeal a weight loss drug denial myself?
Yes. A member can generally submit an appeal under the plan’s process. A doctor-led appeal with relevant medical records may help support the request. The plan’s notice will explain deadlines and required steps.
Does the Medicare GLP-1 Bridge count toward my out-of-pocket maximum?
No. The $50 copay is outside Part D, does not count toward TrOOP, and cannot be reduced by Extra Help.
Are cheap online GLP-1s safe?
Compounded GLP-1 products are not FDA-approved. Check an online pharmacy through safe.pharmacy and keep treatment under a physician’s oversight. Product quality and safety should not be assumed based on advertising or price.
Excerpt: GLP-1 insurance coverage dropped again in 2026 as insurers and employers cut weight loss drugs. Appeal steps, alternatives, and Medicare's $50 Bridge option.